AllSci News
Travere earns US patent for sparsentan IgAN method-of-use through 2037
Travere Therapeutics (Nasdaq: TVTX), headquartered in San Diego, received a notice of allowance from the US Patent and Trademark Office for application…
Psilera closes USD 8.8m seed extension to advance neuroplastogen toward clinical trials
Tampa, Florida-based Psilera, Inc. has closed an oversubscribed USD 8.8 million Series Seed extension round to advance its lead asset, PSIL-006, toward…
Sino Bio takes NMPA priority status for oral drug against IDH1-mutant biliary tract cancer
Sino Biopharmaceutical (HKEX: 01177) has submitted TQB3454, an oral IDH1 inhibitor tablet developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group, for…
Sanofi’s NDA for venglustat in Gaucher disease gets FDA priority status
Sanofi (Euronext: SAN; Nasdaq: SNY) has received priority review from the US FDA for a new drug application (NDA) for venglustat, an…
China grants priority review to Dizal’s Zegfrovy for first-line EGFR exon 20 insertion NSCLC
Dizal Pharmaceutical (SSE: 688192), a Shanghai-based biopharmaceutical company, has submitted a New Drug Application to China’s National Medical Products Administration (NMPA) for…
Immutep’s eftilagimod alfa linked to improved survival in late-stage cancer pooled analysis
Australia-based Immutep Ltd (ASX: IMM; Nasdaq: IMMP) reported that pooled exploratory analysis suggested that patients with late-stage cancer who mounted an immune…
Zenas seeking first approval for CD19/FcgRIIb-targeted obexelimab in IgG4-related disease
Zenas BioPharma (Nasdaq: ZBIO), based in Waltham, Massachusetts, has submitted a Biologics License Application (BLA) to the US FDA for obexelimab, an…
GSK posts latest data showing bepirovirsen producing functional cure for up to 19% of hep B patients
GSK (NYSE: GSK) has reported pivotal Phase III data showing that bepirovirsen, its antisense oligonucleotide (ASO) for chronic hepatitis B, achieved functional…
Apogee secures USD 1.3b from Blackstone for zumilokibart Phase III advancement
San Francisco-based Apogee Therapeutics (Nasdaq: APGE) has announced a strategic financing collaboration with funds managed by Blackstone Life Sciences,...
Australia approves InnoCare’s BTKi Hibruka for mantle cell lymphoma
InnoCare Pharma (HKEX: 09969; SSE: 688428) has received approval from Australia’s Therapeutic Goods Administration (TGA) for Hibruka (orelabrutinib) in relapsed or refractory…
FDA expands label for Ironwood/AbbVie’s Linzess to youngest pediatric FC patients
Ironwood Pharmaceuticals (Nasdaq: IRWD) has received US FDA approval to extend the use of Linzess (linaclotide) to children as young as two…
Bonito Bio and DaltonTx collaborate on agentic AI for CNS-targeted oligotherapeutics delivery
Bonito Biosciences and DaltonTx are combining large-scale ligand screening with agentic AI to tackle one of the most persistent bottlenecks in RNA medicine:...
LifeArc backs Elpida Therapeutics AAV gene therapy programs for three ultra-rare childhood diseases
LifeArc backs Elpida Therapeutics gene therapy push for three ultra-rare childhood diseases
Asahi Kasei licenses ADC bioconjugation platform from The Noguchi Institute
Asahi Kasei Life Science, a subsidiary of Asahi Kasei Corporation (TSE: 3407; OTC: AHKSY), has licensed a glycan-based antibody-drug conjugate...
Q32 Bio raises USD 55m in private placement as bempikibart enters Phase II for alopecia
Waltham, Massachusetts-based Q32 Bio Inc. (Nasdaq: QTTB) announced a USD 55 million private placement of common stock and pre-funded warrants to fund the...
The AllSci Brief
Systematic R&D and deal news. Daily.